NCT06052059: An ongoing trial by Merck Sharp & Dohme LLC
This trial is ongoing. It must report results 1 year, 7 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT06052059 |
|---|---|
| Title | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Program to Evaluate the Efficacy and Safety of MK-7240 in Participants With Moderately to Severely Active Ulcerative Colitis |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Oct. 25, 2023 |
| Completion date | Aug. 1, 2026 |
| Required reporting date | Aug. 1, 2027, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |